Results 1 to 10 of about 325,134 (291)
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
JAMA Neurology, 2023 Key Points Question Is the recent use of direct oral anticoagulants (confirmed ingestion within 48 hours) associated with increased risk of symptomatic intracranial hemorrhage following intravenous thrombolysis for ischemic stroke?T. Meinel, D. Wilson, H. Gensicke, J. Scheitz, P. Ringleb, I. Goganau, J. Kaesmacher, H. Bae, D. Y. Kim, P. Kermer, Kentaro Suzuki, K. Kimura, Kosmas Macha, M. Koga, S. Wada, V. Altersberger, A. Salerno, L. Palanikumar, A. Zini, S. Forlivesi, L. Kellert, J. Wischmann, E. Kristoffersen, J. Beharry, P. Barber, Jae-Beom Hong, C. Cereda, E. Schlemm, Y. Yakushiji, S. Poli, R. Leker, M. Romoli, M. Zedde, Sami Curtze, B. Ikenberg, T. Uphaus, D. Giannandrea, P. Portela, R. Veltkamp, A. Ranta, M. Arnold, U. Fischer, J. Cha, Teddy Y. Wu, J. Purrucker, D. Seiffge, M. Goeldlin, B. Siepen, M. Mueller, M. Beyeler, A. Scutelnic, Simon Jung, A. Mujanović, C. Kurmann, T. Dobrocky, Eike Piechoviak, R. Wiest, A. Hakim, P. Bücke, Zarzitzky Jana, Lichti Carmen, Dmytrow Diana Isabella, J. Ramos, D. Strambo, Menuela Buehrer, N. Simaan, A. Honig, A. Filioglo, I. Grisendi, Laura Ferri, M. Trapasso, Matteo Benini, R. Pascarella, Claudio Moratti, M. Napoli, S. Sumaria, K. Gröschel, M. Hahn, A. Polymeris, C. Traenka, Annaelle Zietz, P. Lyrer, G. M. DeMarchis, S. Thilemann, Ines Piot, L. Enz, N. Peters, M. Katan, A. Brehm, M. Psychogios, Ulrike Prange, N. Spratt, Laurent Roten, B. Chew, Jakub Stefela, R. von Rennenberg, S. Litmeier, Christoph Riegler, M. Klammer, H. Erdur, Hellwig Simon, M. Mauro, L. Marco, Cordici Francesco, B. Sara, Peter Tan, M. Ercegovac, I. Berisavac, D. Haupenthal, L. Gassmann, Armin Marsch, Gabriela Siedler, L. Weir, L. Pesavento, N. Yassi, Stephen Davis, B. Ip, T. Leung, Alexandra Gomez-Exposito, J. Mbroh, J. Tünnerhoff, G. Barbu, Yi Wang, Annerose Mengel, Feil Katharina, M. Kowarik, U. Ziemann, J. Kim, Jihoon Kang, Moon‐Ku Han, B. Kim, K. Choi, Man-Seok Park, Ki-Hyun Cho, J. Kim, Dong-Ick Shin, K. Yum, Dae-Hyun Kim, J. Cha, Jong-Moo Park, K. Kang, Yong Soo Kim, J. Kim, S. Lee, M. Oh, Byung‐Chul Lee, Min Lee, K. Yu, Hong‐Kyun Park, K. Hong, Yong‐Jin Cho, J. Choi, Joong-Goo Kim, Chul-Hoo Kang, S. Sohn, Jeong‐Ho Hong, S. Jang, Hyungjong Park, T. Park, Sang-Soon Park, K. Lee, J. Kwon, Wook-Joo Kim, J. Lee, D. Kwon, Dong-Seok Gwak, Dong-Eog Kim, K. Lee, Sang-Hwa Lee, Chulho Kim, H. Jeong, K. Park, J. S. Lee, Juneyoung Lee, N. Martinez-Majander, G. Sibolt, M. Tiainen, M. Gentile, L. Migliaccio, L. Simonetti, M. Paolucci, Alan Flores, L. Seró, G. Turc, C. Oppenheim, O. Naggara, W. Ben Hassen, J. Benzakoun, Y. Yakushiji, T. Kunieda, G. Kägi, S. Engelter, C. Nolte, B. Kallmünzer, P. Michel, T. Kleinig, J. Fink, O. Rønning, B. Campbell, P. Nederkoorn, G. Thomalla, T. Kunieda, Khouloud Poli, Y. Béjot, Y. Soo, C. Garcia-Esperon, G. Ntaios, C. Cordonnier, J. Marto, G. Bigliardi, François Lun, P. Choi, T. Steiner, X. Ustrell, D. Werring, S. Wegener, A. Pezzini, Houwei Du, J. Martí-Fábregas, D. Cánovas-Vergé, D. Strbian, V. Padjen, S. Yaghi, Christoph Stretz, J. Kim +224 moresemanticscholar +1 more sourceAnticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications
Cells, 2022 Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians possess a broad panel of multiple ...Marco Heestermans, G. Poénou, H. Hamzeh-Cognasse, F. Cognasse, L. Bertoletti +4 moresemanticscholar +1 more sourceAnticoagulants for people hospitalised with COVID-19.
Cochrane Database of Systematic Reviews, 2022 BACKGROUND
The primary manifestation of coronavirus disease 2019 (COVID-19) is respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and thromboembolic events, such as pulmonary embolism, deep vein thrombosis, or ...Ronald Lg Flumignan, V. T. Civile, J. D. D. S. Tinôco, P. I. Pascoal, L. L. Areias, C. Matar, B. Tendal, V. Trevisani, Á. Atallah, L. C. Nakano +9 moresemanticscholar +1 more sourceFactor XI as a Target for New Anticoagulants
Hämostaseologie, 2021 Despite advances in anticoagulant therapy, thrombosis remains the leading cause of morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first anticoagulants to be used successfully for the prevention and treatment of ...J. Fredenburgh, J. Weitzsemanticscholar +1 more sourceLupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
Research and Practice in Thrombosis and Haemostasis, 2022 Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromboplastin time and dilute Russell's viper venom time ...Emmanuel J. Favaloro, Leonardo Pasalicopenaire +3 more sourcesOutcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]
, 2020 Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA +17 morecore +2 more sourcesPatient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...Ashman, N, Green, L, Hull, SA, MacCallum, PK, Mathur, R, Morris, JK, Saja, K +6 morecore +2 more sourcesHow we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania +4 morecore +1 more sourceUse of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 2020 Clarity and guidance is required with regard to the use of direct oral anticoagulants in antiphospholipid syndrome (APS) patients, within the confines of the recent European Medicines Agency recommendations, discrepant recommendations in other ...S. Zuily, H. Cohen, D. Isenberg, S. Woller, M. Crowther, V. Dufrost, D. Wahl, C. Doré, A. Cuker, M. Carrier, V. Pengo, K. Devreese +11 moresemanticscholar +1 more source